The fifth U.K. meeting on nuclear envelope disease and chromatin brought together international experts from across the field of nuclear envelope biology to discuss the advancements in a class of tissue-specific degenerative diseases called the laminopathies. Clinically, these range from relatively mild fat-wasting disorders to the severe premature aging condition known as Hutchinson-Gilford progeria syndrome. Since the first association of the nuclear envelope with human inherited disease in 1994, there has been an exponential increase in an unexpected variety of functions associated with nuclear envelope proteins, ranging from mechanical support and nucleocytoskeletal connections to regulation of chromatin organization and gene expression. This Biochemical Society Focused Meeting reinforced the functional complexity of nuclearassociated diseases, revealed new avenues to be investigated and highlighted the signalling pathways suitable as therapeutic targets.
Introduction
The Nuclear Envelope Disease and Chromatin Organization UK was formed in 2005, to unite and promote collaborations between the growing number of UK research scientists studying tissue-specific degenerative diseases associated with genetic defects in the nuclear envelope proteins emerin, lamin A/C, and nesprin-1 and -2. Collectively, these diseases are known as the laminopathies. Between them, the major clinical symptoms include: cardiovascular dysfunction (dilated cardiomyopathy and atherosclerosis), muscular dystrophy (muscle wasting), lipodystrophy (fat wasting), INM, inner nuclear membrane; iPSC, induced pluripotent stem cell; LINC, linker of nucleoskeleton and cytoskeleton; miRNA, microRNA; MLIP, muscle-enriched A-type lamin-interacting protein; NET, nuclear envelope transmembrane protein; ONM, outer nuclear membrane; ROS, reactive oxygen species; VSMC, vascular smooth muscle cell; ZMPSTE24, zinc metalloprotease Ste24 homologue. 1 To whom correspondence should be addressed (email juliet.ellis@kcl.ac.uk).
diabetes, neuropathy and progeria (premature aging). All of these conditions are life-threatening, and only limited palliative treatment is available, with many patients dying between the teenage and early adulthood years. A major focus of current research is to resolve the enigma of how defective nuclear proteins, primarily disrupting nuclear structure and gene expression, produce such a diverse array of diseases. Although the incidence of these diseases is 1:50 000 or less, the clinical phenotypes generated mimic common medical conditions associated with Western society (e.g. diabetes, atherosclerosis and normal aging). Studying these conditions may therefore also suggest new therapeutic pathways for these ailments too.
By 2009, it was clear that the nuclear envelope disease field had escalated considerably, not only in the number of molecular pathways involved [e.g. ROS (reactive oxygen species)-induced DNA damage], but also in the number of diseases (e.g. novel progeroid syndromes) which are dependent on nuclear envelope function. Therefore our 2011 meeting broadened its programme to include these advancements. The present article discusses each of the four meeting session themes, highlighting the important findings, with reference to some of the accompanying reviews in this volume of Biochemical Society Transactions. Sadly, space considerations preclude mentioning every communication and we apologize to meeting contributors whose work has not been discussed here.
Nuclear envelope proteins and disease
The nuclear envelope is composed of a double membrane system interspersed with nuclear pore complexes, separating nuclear from cytoplasmic functions. The INM (inner nuclear membrane) juxtaposes the nuclear lamina, a meshwork-like structure mainly composed of the intermediate filament proteins nuclear lamins A, B and C, which in turn faces the nuclear interior. The ONM (outer nuclear membrane) is an extension of the ER (endoplasmic reticulum) network, but also contains a distinct protein subpopulation. The INM is estimated to accommodate at least 100 different transmembrane proteins, of which many are tissue-specific and, along with the ONM, is instrumental in regulating both nuclear architectural changes and nucleocytoskeletal functions. The latter involves a macroprotein complex termed the 'LINC (linker of nucleoskeleton and cytoskeleton) complex' [1] , the main components being SUN and nesprin proteins located in the INM and ONM respectively. The prime functions of the LINC complex are to control nuclear positioning within the cell and to maintain nuclear structure and cellular tensegrity, the latter additionally involving filament links to the cell surface.
Lamin A and C are alternatively spliced products of the LMNA gene. In-frame LMNA mutations are responsible for at least ten different tissue-specific degenerative diseases, the laminopathies [2] . Clinically, laminopathies lie on a sliding clinical spectrum, with overlapping phenotypes. Muscular dystrophy, dilated cardiomyopathy and CharcotMarie-Tooth axonal neuropathy affect striated muscle and/or peripheral nerves, familial partial lipodystrophy of Dunnigan type 2 affects subcutaneous fat distribution, and the metabolism and premature aging syndromes [HGPS (HutchinsonGilford progeria syndrome), restrictive dermopathy and mandibuloacral dysplasia] affect nearly all tissues. Intraand inter-familial variability also occur, indicative of the importance of the genetic background in disease penetrance. Only now are candidate modifier genes emerging. Gisele Bonne [3] presented data locating a modifier of myopathic symptoms to a locus on chromosome 2, a region including desmin and myosin light chain genes. Furthermore, there must be genes other than LMNA which give rise to clinically indistinguishable forms of some of the laminopathies, since only about 46% of patients clinically identified with EDMD (Emery-Dreifuss muscular dystrophy) arise from mutations in lamin A/C, emerin, nesprin-1/2 or FHL1 (four-and-ahalf LIM domain 1). Both other LINC components e.g. SUN1/2, nesprin-3 and non-LINC nuclear-binding partners [e.g. LUMA/TMEM43 (transmembrane protein 43), GCL (germ cell-less), Btf (Bcl-2-associated transcription factor)] are likely contenders [4] . In this regard, Carlos López-Otín and colleagues has recently identified [5] and reported at this meeting that mutations in the emerin binding partner and DNA-binding protein, BAF1 (barrier to autointegration factor 1), can lead to a milder form of progeria called Néstor-Guillermo progeria syndrome.
Lamin A/C has a large number of tissue-specific and ubiquitously expressed binding partners, which increases by one or two annually, illustrating its central role in both nuclear function and disease. These partners include nuclear lamina and INM proteins, as well as chromatin and DNA-binding proteins (transcription factors, cofactors and regulators), and cell-cycle-dependent kinases/cyclins. Patrick Burgon described a novel muscle-enriched DNAbinding protein termed MLIP (muscle-enriched A-type lamin-interacting protein). It interacts with regions adjacent to transcription factor genes, suggesting that it may be yet another transcriptional regulator associated with lamins. Interestingly, conditional MLIP hemizygous knockout mice develop dilated cardiomyopathy and lipodystrophy, two of the laminopathy phenotypes [6] . Another novel lamin A/Cbinding partner was described by Jose González: SNX6 (sorting nexin 6). This is an intracellular trafficking sorting protein, directing lamin A from the cytoplasm into the nucleus and its subsequent incorporation into the lamina [7] .
Aging and progeria
Lamin A is the end-product of several consecutive posttranslational modification steps initiating from a prelamin A precursor [8] . These modifications include farnesylation, methylation and a couple of proteolytic cleavage events catalysed by the metalloprotease ZMPSTE24 (zinc metalloprotease Ste24 homologue)/FACE1 (farnesylated proteinsconverting enzyme 1), the last step removing the added farnesyl group. Functional reasons underlying such a complex maturation process are unclear. Mounting evidence suggests that several intermediates, particularly the initial prelamin A protein, have functional roles dependent on the cell differentiation state and they also have a higher affinity than mature lamin A for the nuclear lamina [8] . In addition, there are LMNA/ZMPSTE24 mutations generating constitutively farnesylated prelamin A intermediates, including progerin (the truncated form of prelamin A associated with HGPS), that are toxic upon accumulation. Progeroid patients display aged VSMCs (vascular smooth muscle cells) similar to those in normal old people. Thus incorrectly processed prelamin A contributes towards the molecular perturbations associated with several progeroid and lipodystrophy syndromes, as well as being a marker for normal VSMC aging [9] .
Progeroid syndromes and aged VSMCs are also associated with above normal levels of both ROS and DNA doublestrand breaks; the latter due to a failure of one or more DNA-repair mechanisms. Both result in the persistence of DNA damage. However, the signalling pathway(s) linking progeria-causing LMNA mutations and perturbed cellular stress pathways remain elusive, since they are independent of perturbed prelamin A processing. Several speakers presented data proposing possible connecting avenues. Yue Zou illustrated that aberrantly functioning DNA replication forks in HGPS-derived cells prohibit DNA break repair because the nucleotide excision repair protein, XPA (xeroderma pigmentosum group A), is relocated to DNA breaks, blocking entry of the DNA-repair protein machinery [10] . Christopher Hutchison demonstrated that ROS scavengers are inefficient at dissipating ROS in HGPS cells and so they accrue [11] . miRNA (microRNA) dysregulation was recently shown to be important in EDMD pathology by the Shackleton group [12] , and, from studies on ZMPSTE24 mouse models of progeria, it suggests they are important in progeria too. Carlos López-Otín reported upregulation of miR-29a, miR-29b and miR-29c in Zmpste24-deficient mice [13] . These miRNAs play a pivotal role in controlling cell survival and proliferation by modulating the DNA-damage response in a p53-dependent manner. Taking these two findings together, it suggests that other aspects of laminopathy pathology may also be explained by dysfunctional miRNA regulation.
Nucleocytoplasmic connections
The LINC complex creates a means to both maintain and regulate mechanical coupling between the nucleus and cytoskeleton and indirectly to the cell surface [1] . Since LINC complex components are selectively affected in the laminopathies, it is not surprising that LMNA mutations disturb a range of intracellular events dependent on force transmission [14] . These include nuclear and centrosome positioning, cell division, polarization, adhesion and motility. Tissue morphogenesis is dependent on nuclear movement too, and Didier Hodzic reviews the role of the LINC complex in both skeletal muscle and central nervous system development [15] . Within the LINC complex, it is the nesprin gene family [16] which provides the interaction between the SUN proteins at the INM to cytoskeletal filaments, with nesprin-1/2 isoforms interacting directly with actin and nesprin-3, via the linker protein plectin, to intermediate filaments. However, with the likelihood of further LINC components remaining to be identified and with the number of nesprin family genes/isoforms seeming to be exponentially growing, there is clearly much to learn about the functionality of nucleocytoskeletal connections. Indeed, nesprin-3 appears to play a more passive role than nesprin-1/-2, since it stabilizes nuclear anchorage, rather than orchestrating it [17] .
Centrosome-nuclear attachment is mediated by adapterdependent interactions involving microtubules, which are regulated by components of the LINC complex. It was thus not surprising to learn that nesprin-3 connects to the microtubules via the cytoskeletal cross-linkers BPAG1 (bullous pemphigoid antigen 1) (isoform from the dystonin gene; belongs to plakin protein family) and MACF1 (microtubule-actin cross-linking factor 1) [17] , nesprin-4 to the molecular motor kinesin 1, and nesprin -1/2 to dynein. It was established long ago that the ER network (a continuation of the ONM) lies alongside the microtubule network [18] and thus one might expect to find that INM/ONM proteins also associate with microtubules. Einar Hallberg presented data on such an INM protein, Samp1, identifying it as additionally sorting with the mitotic spindle [19] . The traditional model for metazoan mitosis precludes inclusion of membranes, and so this work introduces a new concept to the role of nuclear envelope proteins in cell division.
Nuclear envelope-chromatin interactions
Chromatin architecture divides itself into heterochromatic (non-active) at the nuclear periphery and euchromatic (active) in the interior, but it is a dynamic ratio, changing during the course of the cell cycle, and during cell differentiation and development. Even individual chromosome territories are dynamic, with movement probably driven by actinmyosin contraction [20] and their exact positions being celltype-dependent. Nuclear envelope INM and lamina proteins are central to chromatin-nuclear envelope interactions. The INM proteins containing the conserved LEM [LAP2 (lamina-associated polypeptide 2)/emerin/MAN1] domain, bind not only to nuclear lamins, but also directly to DNAbinding proteins such as BAF1, transcriptional regulators (e.g. retinoblastoma), transcription factors (e.g. GCL, Lmo-7, Btf or β-catenin) and to chromatin [21] . These interactions implicate the nuclear envelope in regulating chromatin organization and gene expression, both of which are perturbed in many of the laminopathies. However, of the 90 or so NETs (nuclear envelope transmembrane proteins) whose functions remain to be elucidated, some of them are likely to contribute novel functional roles towards nuclear envelope-chromatin interactions. For instance, several NETs, both INM and ONM, are now identified with specific roles in cell-cycle regulation [22] , which may contribute to the cellular senescence observed in both the muscular dystrophies and progeria-type laminopathies.
Therapeutic pathways
Cellular accumulation of both prelamin A and progerin occurs in normal individuals as part of the aging process. Understanding these pathways is attractive to those interested in developing anti-aging therapeutics. Loren Fong (University of California) discussed in the plenary lecture the various therapeutic options available for progeroid patients. Since the toxic effect of lamin A intermediates is linked to their farnesylation, studying the effect of FTIs (farnesyltransferase inhibitors) was an obvious first step. In pre-clinical studies, FTIs restored nuclear function and they are now in clinical trials. A second potential therapy targeting the same cholesterol pathway as FTIs is also in pre-clinical trials. This involves the combined administration of the cholesterol-lowering drug pravastatin with the bisphosphonate zoledronate (used to treat osteoporosis). To date, HGPS primary skin cultures and animal models of progeria have been used for these studies, but both possess shortcomings with respect to accurately mimicking the condition. With the creation of iPSCs (induced pluripotent stem cells), this issue is beginning to be addressed. Xavier Nissan [23] presented work demonstrating the effects of these drugs on iPSCs generated from HGPS patients' dermal fibroblasts and converted into mesenchymal stem cells. This cell line proved to be an accurate model for HGPS. Such success will hopefully stimulate others to generate iPSC lines from different laminopathy patients, so that they too can benefit from this novel cellular disease model.
The future
This meeting series goes from strength to strength, and this year was no exception. We linked laminopathies to new signalling pathways and protein/DNA players, alongside a comprehensive update of the laminopathy field. This provided the driving force to initiate new collaborations, the fruits of which we all look forward to hearing about at the next meeting.
